Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Liver Cancer"
DOI: 10.1159/000512170
Abstract: Immune checkpoint inhibitor (ICI) monotherapy yields lower response rates and higher progressive disease (PD) rates than the recently developed combination immunotherapy regimen [1, 2]. Addition of an anti-vascular endothelial growth factor (VEGF) antibody/ tyrosine kinase… read more here.
Keywords: hepatocellular carcinoma; impact anti; limited impact; monotherapy ... See more keywords